Stéphane Bancel: Moderna’s biotech whizz who changed the world

Stéphane Bancel had a safe job as CEO of a French multinational when he decided to risk it all on a promising but unproven medical technology. The bet paid off handsomely.

If Stéphane Bancel ever questioned his ability to move markets, he got his answer last week. The Moderna CEO’s observation that existing vaccines will be less effective at tackling Omicron than earlier strains of Covid-19 rattled investors sufficiently to spark another global lurch downwards, says the Financial Times. The mood has since lightened – there are signs the variant may prove less serious than feared. But Moderna and other vaccine-makers still have their work cut out. Bancel reckons Moderna could make between two and three billion Omicron-targeted doses next year, but it’s a balancing act. “It would be risky,” he says, to shift the entire production capacity into the fight when other variants are still in circulation.

At the vanguard of science

Moderna is now such a household name that it’s almost a shock to recall that its sole commercial product is the Covid-19 vaccine. “Before the pandemic, Moderna was simply a heavily loss-making biotech with unproven technology,” says The Sunday Times. But delivery of its mRNA jab “has cemented its place at the vanguard of scientific discovery”. It has also made a small fortune for Bancel, who owns around 8% of the Cambridge, Massachusetts-based outfit’s shares, which have jumped by more than 1,000% since it floated on Nasdaq in 2018. In just over a decade since Moderna was founded – on the-then radical hunch that mRNA could be used to treat cancer, diabetes and genetic diseases – its market value has shot up to nearly $115bn. As a peer observes: “The pandemic came almost as a blessing to prove the technology”.

According to early investor Baillie Gifford, the pugnacious Frenchman has always stood out from the crowd as “a relentless risk optimiser”. Bancel famously quit a “safe job”, as CEO of the French diagnostics multinational BioMérieux, to join the fledgling Moderna in 2011 – telling his photographer wife, Brenda, there was just a 5% chance that its “crazy idea” would work. As he observed on a recent Distillations podcast, he couldn’t forego the “chance of changing medicine forever”. 

The emperor was clothed

Born in 1972, Bancel grew up in Marseilles, the son of an engineer and a doctor – fusing these professions into his own life when he chose to study biomolecular engineering at École Centrale in Paris. His subsequent move to Minnesota for a masters opened up the world of US business. Bancel’s first job was at BioMérieux, which had sponsored his MBA at Harvard. At 29 he joined the US drug-maker Eli Lilly, before returning to lead BioMérieux when he was just 34.

In Moderna’s early days, cash was so tight it often struggled to keep the lights on for six months at a time. Bancel, who had “an almost messianic reverence for the mRNA technology”, took an all or nothing approach: you either got with the plot, or you were out, noted industry journal Stat in 2016. Reports of conflicts and defections multiplied – even as Bancel succeeded in persuading the industry’s big-hitters of Moderna’s potential (forging a transforming $240m partnership with AstraZeneca in 2013). He later consulted the HR departments of some tech firms for “tips on employee retention”. The charge of scientific critics back then was that Moderna was “a case of emperor’s new clothes”. Whatever Bancel’s current challenges, he has been vindicated. As the world queues up for Moderna shots, you don’t hear much talk of naked emperors.

Recommended

The best 0% balance-transfer credit cards
Credit cards

The best 0% balance-transfer credit cards

These 0% balance transfer credit cards offer some of the best deals on the market today.
26 May 2023
Where do we go from here?
Investments

Where do we go from here?

A new series of interviews from MoneyWeek
26 May 2023
Best savings accounts – May 2023
Savings

Best savings accounts – May 2023

Interest rates have been creeping up - we look at the best savings accounts on the market right now.
26 May 2023
The best one-year fixed savings accounts - May 2023
Savings

The best one-year fixed savings accounts - May 2023

You can now earn 5% on 1 year fixed savings accounts - the best rate seen in 14 years. We have all the latest rates available now.
26 May 2023

Most Popular

Nationwide to give £100 cash boost to customers
Personal finance

Nationwide to give £100 cash boost to customers

Nationwide Building Society is giving customers £100 as it reinvests profits. Dubbed the Nationwide Fairer Share scheme, we look at who is eligible.
22 May 2023
Share tips of the week – 26 May
Investments

Share tips of the week – 26 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
25 May 2023
Holiday rip-off: Millions of travellers hit with hidden costs by using debit card abroad
Personal finance

Holiday rip-off: Millions of travellers hit with hidden costs by using debit card abroad

A family of four on a week-long trip to France could pay an extra £212 in fees by using their everyday bank card compared to the lowest-cost option, a…
23 May 2023